EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

ROS-Responsive Nanosystem Targeted Co-Delivery YC-1 and Regorafenib to Alleviate Hypoxia Enhancing Hepatocellular Carcinoma Therapy

Liming Song, Yahui Wu, Senfeng Zhao, Yin Liu, Zhipu Liu, Yunpeng Zhai, Jiahui Cao, Yaning Xia, Ruopeng Liang, Weijie Wang, Rongtao Zhu, Binghua Sun und 2 weitere

International Journal of Nanomedicine · 2025-07 · Volume 20 · 8481-8496

DOI: 10.2147/ijn.s518120 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Nanomedicine, 2025-07. Verfasst von Liming Song und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People's Republic of Ch…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Pyridines, Indazoles. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The current treatment of hepatocellular carcinoma (HCC) is confronted with anoxic drug resistance and significant side effects. To address these issues, a Reactive Oxygen Species (ROS)-responsive and targeted nano drug delivery system named REG/YC-1@PTP-RGD NPs (RYP-RGD NPs) was designed for the co-delivery of Regorafenib (REG) and the hypoxia inhibitor 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole (YC-1).

Methods

RYP-RGD NPs were fabricated through the self-assembly method. A series of techniques, such as transmission electron microscopy (TEM), UV-visible spectroscopy, and others, were employed to characterize their properties. In Vitro investigations encompassed drug release assays, cytotoxicity evaluations using Cell Counting Kit-8 (CCK-8) and other methods, cell uptake experiments, and Western blot analysis. In vivo, the biodistribution of RYP-RGD NPs was tracked by IVIS imaging, and their antitumor efficacy and biosafety were assessed in a HepG2 tumor-bearing mouse model with histological staining and biochemical analysis.

Results

RYP-RGD NPs exhibited a spherical morphology with an appropriate size and excellent dispersion. They demonstrated ROS-triggered drug release behavior. In vitro studies revealed good tumor-targeting ability, enhanced cytotoxicity against HCC cells, and the downregulation of hypoxia-inducible factor-1α (HIF-1α) by YC-1. In vivo experiments showed improved tumor targeting, significant inhibition of tumor growth, and lower toxicity compared to single drugs.

Conclusion

The successfully developed RYP-RGD NPs offer a novel strategy for HCC treatment. They enhance drug targeting, synergistically boost the therapeutic effect, and maintain biosafety, showing great potential for clinical translation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsPyridinesIndazolesPhenylurea CompoundsNanoparticle Drug Delivery SystemAnimalsHumansReactive Oxygen SpeciesMiceHep G2 CellsDrug LiberationTissue DistributionAntineoplastic AgentsMice, NudeNanoparticlesMice, Inbred BALB CDrug Delivery SystemsXenograft Model Antitumor Assays

Stichwörter der Autor:innen

drug deliveryhypoxiananocarrierreactive oxygen speciesregorafenib

Substanzen

regorafenibPyridinesReactive Oxygen Species3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazoleIndazolesPhenylurea CompoundsAntineoplastic AgentsNanoparticle Drug Delivery System

Autor:innen und Institutionen

  • Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People's Republic of China.
  • Institute of Hepatobiliary and Pancreatic Diseases, Zhengzhou University, Zhengzhou, 450052, People's Republic of China.
  • Zhengzhou Basic and Clinical Key Laboratory of Hepatopancreatobiliary Diseases, Zhengzhou, 450052, People's Republic of China.
  • Department of Magnetic Resonance Imaging, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People's Republic of China.
  • Department of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People's Republic of China.

ORCID-Profile: Yupeng Shi

Zitieren

APA

Song, L., Wu, Y., Zhao, S., Liu, Y., Liu, Z., Zhai, Y., Cao, J., Xia, Y., Liang, R., Wang, W., Zhu, R., Sun, B., Shi, Y., & Sun, Y. (2025). ROS-Responsive Nanosystem Targeted Co-Delivery YC-1 and Regorafenib to Alleviate Hypoxia Enhancing Hepatocellular Carcinoma Therapy. International Journal of Nanomedicine, Volume 20, 8481-8496. https://doi.org/10.2147/ijn.s518120

Vancouver

Song L, Wu Y, Zhao S, Liu Y, Liu Z, Zhai Y, et al. ROS-Responsive Nanosystem Targeted Co-Delivery YC-1 and Regorafenib to Alleviate Hypoxia Enhancing Hepatocellular Carcinoma Therapy. International Journal of Nanomedicine. 2025;Volume 20:8481-8496. doi:10.2147/ijn.s518120

BibTeX
@article{Song2025,
  author = {Song, Liming and Wu, Yahui and Zhao, Senfeng and Liu, Yin and Liu, Zhipu and Zhai, Yunpeng and Cao, Jiahui and Xia, Yaning and Liang, Ruopeng and Wang, Weijie and Zhu, Rongtao and Sun, Binghua and Shi, Yupeng and Sun, Yuling},
  title = {ROS-Responsive Nanosystem Targeted Co-Delivery YC-1 and Regorafenib to Alleviate Hypoxia Enhancing Hepatocellular Carcinoma Therapy},
  journal = {International Journal of Nanomedicine},
  year = {2025},
  volume = {Volume 20},
  pages = {8481--8496},
  doi = {10.2147/ijn.s518120}
}
Kostenlos starten →